United Therapeutics/$UTHR
1D1W1MYTD1Y5YMAX
Capital at risk
About United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
- Ticker
- $UTHR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,400
- Headquarters
- Silver Spring, United States
- Website
- www.unither.com
UTHR Metrics
BasicAdvanced
$21B
17.90
$27.95
0.56
-
Price and volume
Market cap
$21B
Beta
0.56
52-week high
$609.35
52-week low
$397.00
Average daily volume
582K
Financial strength
Current ratio
5.732
Quick ratio
4.891
Interest coverage (TTM)
117.06%
Profitability
EBITDA (TTM)
1,496.2
Gross margin (TTM)
86.14%
Net profit margin (TTM)
41.56%
Operating margin (TTM)
44.53%
Effective tax rate (TTM)
16.66%
Revenue per employee (TTM)
$2,250,000
Management effectiveness
Return on assets (TTM)
11.61%
Return on equity (TTM)
19.32%
Valuation
Price to earnings (TTM)
17.903
Price to revenue (TTM)
6.868
Price to book
3.34
Price to tangible book (TTM)
3.4
Price to free cash flow (TTM)
19.922
Free cash flow yield (TTM)
5.02%
Free cash flow per share (TTM)
25.115
Growth
Revenue change (TTM)
2.49%
Earnings per share change (TTM)
9.04%
3-year revenue growth (CAGR)
14.33%
10-year revenue growth (CAGR)
7.21%
3-year earnings per share growth (CAGR)
16.53%
10-year earnings per share growth (CAGR)
3.05%
What the Analysts think about UTHR
Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.
Analyst projections of the future price of United Therapeutics stock.
Bulls say / Bears say
FDA accepted the NDA for ralinepag to treat PAH, which, if approved, would expand United Therapeutics’ portfolio beyond treprostinil-based therapies with an oral, once-daily prostacyclin option (Reuters)
FDA accepted the supplemental NDA for nebulized Tyvaso to treat idiopathic pulmonary fibrosis on September 2, 2026, potentially granting seven-year orphan exclusivity and markedly enlarging the addressable market (BusinessWire)
Tyvaso DPI exited Q2 2026 at record levels of patient starts, referrals, commercial patients, and total patients, demonstrating strong underlying demand for United Therapeutics’ core revenue driver (United Therapeutics IR)
Q2 2026 revenue fell 1.9% year-over-year to $783.3 million, missing consensus forecasts of ~$805.6 million and signaling potential headwinds in patient uptake or pricing pressure (Reuters)
The decline in Q2 performance was driven in part by an 18% year-over-year drop in U.S. quantities sold of nebulized Tyvaso, underscoring challenges in its injectable prostacyclin segment (Reuters)
Key treprostinil patents expire between 2026 and 2028, and under a settlement, Watson is permitted to market a generic nebulized Tyvaso as early as January 2026, posing near-term revenue erosion risk (SEC 2025; SEC Q2 2026)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
UTHR Financial Performance
Revenues and expenses
UTHR Earnings Performance
Company profitability
Upcoming events
No upcoming events
UTHR News
AllArticlesVideos
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
Business Wire3 weeks ago
United Therapeutics Q2 Earnings Call Highlights
MarketBeat1 month ago
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
Business Wire1 month ago
Funds containing UTHR
AllUSDGBPEUR
Fund name | Fund size | $UTHR weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.43% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.43% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.61% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.61% |
iShares Edge MSCI World Minimum Volatility$MVOL | $2.6B | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.